Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitors

Journal of Andrology

Volumn 33, Issue 6, 2012, Pages 1305-1322

  Porst, Hartmut ^a   Brock, Gerald B ^b   Kula, Krzysztof ^c   Moncada, Ignacio ^d   Montorsi, Francesco ^e   Basson, Bruce R ^f   Kinchen, Kraig ^f   Aversa, Antonio ^g  

^a Hamburg ^*  (Germany)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d HOSPITAL LA ZARZUELA   (Spain)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f ELI LILLY AND COMPANY   (United States)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Drug therapy; Efficacy; Endothelium; Erection; Morning; Nocturnal; Peripheral arterial tonometry; Phosphodiesterases; Psychosocial assessments; Tolerability; Treatment outcome

Indexed keywords

PLACEBO; TADALAFIL;

ADULT; ARTICLE; BACKACHE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; ERECTILE DYSFUNCTION INVENTORY OF TREATMENT SATISFACTION; HEADACHE; HUMAN; IMPEDANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT SATISFACTION; PENIS ERECTION; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SELF ESTEEM AND RELATIONSHIP QUESTIONNAIRE; SELF REPORT; SOCIAL PSYCHOLOGY;

ADULT; CARBOLINES; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; ERECTILE DYSFUNCTION; HUMANS; HYPEREMIA; MALE; MIDDLE AGED; PENILE ERECTION; PERSONAL SATISFACTION; PHOSPHODIESTERASE 5 INHIBITORS; PLACEBOS; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84874405267     PISSN: 01963635     EISSN: 19394640     Source Type: Journal    
DOI: 10.2164/jandrol.111.015289     Document Type: Article

References (84)

1. Althof SE, Cappelleri JC, Shpilsky A, Stecher V, Diuguid C, Sweeney M, Duttagupta S. Treatment responsiveness of the Self-Esteem And Relationship questionnaire in erectile dysfunction. Urology. 2003;61:888-892.
2. Althof SE, Corty EW, Levine SB, Levine F, Burnett AL, McVary K, Stecher V, Seftel AD. EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology. 1999;53:793-799.
3. Althof SE, O'Leary MP, Cappelleri JC, Glina S, King R, Tseng LJ, Bowler JL. Self-esteem, confidence, and relationships in men treated with sildenafil citrate for erectile dysfunction: results of two double-blind, placebo-controlled trials. J Gen Intern Med. 2006a; 21:1069-1074.
4. Althof SE, O'Leary MP, Cappelleri JC, Hyidsten K, Stecher VJ, Glina S, King R, Siegel RL; International SEAR Study Group. Sildenafil citrate improves self-esteem, confidence, and relationships in men with erectile dysfunction: results from an international, multicenter, double-blind, placebo-controlled trial. J Sex Med. 2006b; 3:521-529.
5. Aversa A. Sexual dysfunction: a new tool for early identification of penile endothelial dysfunction. Nat Rev Urol. 2012;9(4):182-183.
6. Aversa A, Francomano D, Bruzziches R, Pili M, Natali M, Spera G, Lenzi A. The application of digital pulse amplitude tonometry to the diagnostic investigation of endothelial dysfunction in men with erectile dysfunction. Andrologia. 2011;43:9-15.
7. Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res. 2007;19:200-207.
8. Bickel C, Rupprecht HJ, Blankenberg S, Espiniola-Klein C, Schlitt A, Rippin G, Hafner G, Treude R, Othman H, Hofmann KP, Meyer J AtheroGene Investigators. Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol. 2002;89:901-908.
9. Billups KL, Kaiser DR, Kelly AS, Wetterling RA, Tsai MY, Hanson N, Bank AJ. Relation of C-reactive protein and other cardiovascular risk factors to penile vascular disease in men with erectile dysfunction. Int J Impot Res. 2003;15:231-236.
10. Bocchio M, Desideri G, Scarpelli P, Necozione S, Properzi G, Spartera C, Francavilla F, Ferri C, Francavilla S. Endothelial cell activation in men with erectile dysfunction without cardiovascular risk factors and overt vascular damage. J Urol. 2004;171:1601-1604.
11. Bocchio M, Pelliccione F, Passaquale G, Mihalca R, Necozione S, Desideri G, Francavilla F, Ferri C, Francavilla S. Inhibition of phosphodiesterase type 5 with tadalafil is associated to an improved activity of circulating angiogenic cells in men with cardiovascular risk factors and erectile dysfunction. Atherosclerosis. 2008;196:313-319.
12. Bohm F, Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res. 2007; 76:8-18.
13. Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Kuvin JT, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. 2004;44:2137-2141.
14. Boutouyrie P, Achouba A, Trunet P, Laurent S EXPLOR Trialist Group.Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension. 2010;55:1314-1322.
15. Brock G, Tu LM, Linet OI. Return of spontaneous erection during long-term intracavernosal alprostadil (Caverject) treatment. Urology. 2001;57:536-541.
16. Cappelleri JC, Althof SE, Siegel RL, Shpilsky A, Bell SS, Duttagupta S. Development and validation of the Self-Esteem and Relationship (SEAR) questionnaire in erectile dysfunction. Int J Impot Res. 2004;16:30-38.
17. Cappelleri JC, Althof SE, Siegel RL, Stecher VJ, Tseng LJ, Duttagupta S. Association between the Erectile Dysfunction Inventory of Treatment Satisfaction and the Self-Esteem and Relationship Questionnaire following treatment with sildenafil citrate for men with erectile dysfunction. Value Health. 2005; 8(suppl 1):S54-S60.
18. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology. 1999;54: 346-351.
19. Caretta N, Palego P, Ferlin A, Garolla A, Bettella A, Selice R, Foresta C. Resumption of spontaneous erections in selected patients affected by erectile dysfunction and various degrees of carotid wall alteration: role of tadalafil. Eur Urol. 2005;48:326-331.
20. Caretta N, Palego P, Schipilliti M, Ferlin A, Di Mamro A, Foresta C. Cavernous artery intima-media thickness: a new parameter in the diagnosis of vascular erectile dysfunction. J Sex Med. 2009; 6:1117-1126.
21. Carson C, Shabsigh R, Segal S, Murphy A, Fredlund P, Kuepfer C. Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiarycare academic centers. Urology. 2005;65:353-359.
22. Carson CC, Rajfer J, Eardley I, Carrier S, Denne JS, Walker DJ, Shen W, Cordell W. The efficacy and safety of tadalafil: an update. Br J Urol Int. 2004;93:1276-1281.
23. Chen CH, Cheng BC, Leu S, Chen CH, Tsai TH, Leu S, Chang HW, Chung SY, Chua S, Yeh KH, Chen YL, Yip HK. Circulating level of endothelial progenitor cells in healthy Taiwanese. Acta Cardiol Sing. 2010;26:94-100.
24. Costa C, Virag R. The endothelial-erectile dysfunction connection: an essential update. J Sex Med. 2009;6:2390-2404.
25. Dishy V, Sofowora G, Harris PA, Kandcer M, Zhan F, Wood AJ, Stein CM. The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men. Clin Pharmacol Ther. 2001;70:270-279.
26. Donatucci CF, Wong DG, Giuliano F, Glina S, Dowsett SA, Watts S, Sorsaburu S. Efficacy and safety of tadalafil once daily: considerations for the practical application of a daily dosing option. Curr Med Res Opin. 2008;24:3383-3392.
27. Esposito K, Ciotola M, Maiorino MI, Giugliano F, Autorino R, De Sio M, Jannini E, Lenzi A, Giugliano D. Circulating CD34+ KDR+ endothelial progenitor cells correlate with erectile function and endothelial function in overweight men. J Sex Med. 2009;6:107-114.
28. European Medicines Agency. Cialis summary of product characteristics 2012. Available at http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Product_Information/human/000436/WC500026318.pdf. Accessed September 28, 2012.
29. Foresta C, Caretta N, Lana A, Cabrelle A, Palu G, Ferlin A. Circulating endothelial progenitor cells in patients with erectile dysfunction. Int J Impot Res. 2005a;17:288-290.
30. Foresta C, Caretta N, Lana A, De Toni L, Biagioli A, Vinanzi C, Ferlin A. Relationship between vascular damage degrees and endothelial progenitor cells in patients with erectile dysfunction: effect of vardenafil administration and PDE5 expression in the bone marrow. Eur Urol. 2007;51:1411-1417.
31. Foresta C, De Toni L, Biagioli A, Ganz F. Magagna S, Caretta N. Increased levels of osteocalcin-positive endothelial progenitor cells in patients affected by erectile dysfunction and cavernous atherosclerosis. J Sex Med. 2010a;7:751-757.
32. Foresta C, De Toni L, Garolla A, Ferlin A, Zuccarello D. The PDE5 inhibitor sildenafil increases circulating endothelial progenitor cells and CXCR4 expression. J Sex Med. 2009a;6:369-372.
33. Foresta C, De Toni L, Magagna S, Galan A, Garolla A. Phosphodiesterase-5 inhibitor tadalafil acts on endothelial progenitor cells by CXCR4 signalling. Curr Drug Deliv. 2010b;7:274-282.
34. Foresta C, Di Mambro A, Caretta N, De Toni L, Zuccarello D, Ferlin A. Effect of vardenafil on endothelial progenitor cells in hypogonadotrophic hypogonadal patients: role of testosterone treatment. Clin Endocrinol (Oxf). 2009b;71:412-416.
35. Foresta C, Ferlin A, De Toni L, Lana A, Vinanzi C, Galan A, Caretta N. Circulating endothelial progenitor cells and endothelial function after chronic tadalafil treatment in subjects with erectile dysfunction. Int J Impot Res. 2006;18:484-488.
36. Foresta C, Lana A, Cabrelle A, Ferigo M, Caretta N, Garolla A, Palu G, Ferlin A. PDE-5 inhibitor, Vardenafil, increases circulating progenitor cells in humans. Int J Impot Res. 2005b;17:377-380.
37. Foresta C, Palego P, Schipilliti M, Selice R, Ferlin A, Caretta N. Asymmetric development of peripheral atherosclerosis in patients with erectile dysfunction: an ultrasonographic study. Atherosclerosis. 2008;197:889-895.
38. Gazzaruso C, Giordanetti S, De Amici E, Bertone G, Falcone C, Geroldi D, Fratino P, Solerte SB, Garzaniti A. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation. 2004;110:22-26.
39. Gazzaruso C, Pujia A, Solerte SB, Amici ED, Emanuele E, Falcone C, Geroldi D, Giustina A, Garzaniti A. Erectile dysfunction and angiographic extent of coronary artery disease in type II diabetic patients. Int J Impot Res. 2006;18:311-315.
40. Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, Couture P, Dufour R, Fodor G, Francis GA, Grover S, Gupta M, Hegele RA, Lau DC, Leiter L, Lewis GF, Lonn E, Mancini GB, Ng D, Pearson GJ, Sniderman A, Stone JA, Ur E. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol. 2009;25:567-579.
41. Giugliano F, Esposito K, Di Palo C, Ciotola M, Giugliano G, Marfella R, D'Armiento M, Giugliano D. Erectile dysfunction associates with endothelial dysfunction and raised proinflammatory cytokine levels in obese men. J Endocrinol Invest. 2004; 27:665-669.
42. Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised. DHEW Publication No. ADM 76-338. Rockville, MD: National Institute of Mental Health; 1976:218-222.
43. Hatzichristou D, Gambla M, Rubio-Aurioles E, Buvat J, Brock GB, Spera G, Rose L, Lording D, Liang S. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med. 2008;25:138-146.
44. Jackson G. Editorial comment on Caretta N et al. Resumption of spontaneous erections in selected patients affected by erectile dysfunction and various degrees of carotid wall alteration: role of tadalafil. Eur Urol. 2005;332.
45. Knoll LD, Abrams JH. Application of nocturnal electrobioimpedance volumetric assessment: a feasibility study in men without erectile dysfunction. J Urol. 1999a;161:1137-1140.
46. Knoll LD, Abrams JH. Nocturnal electrobioimpedance volumetric assessment of patients with erectile dysfunction. Urology. 1999b; 53:1200-1204.
47. Levine LA, Carroll RA. Nocturnal penile tumescence and rigidity in men without complaints of erectile dysfunction using a new quantitative analysis software. J Urol. 1994;152:1103-1107.
48. Martin-Morales A, Haro JM, Beardsworth A, Bertsch J, Kontodimas S. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS). Eur Urol. 2007;51:541-550.
49. McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med. 2004;1:292-300.
50. Mizuno I, Fuse H, Fujiuchi Y, Nakagawa O, Akashi T. Comparative study between audiovisual sexual stimulation test and nocturnal penile tumescence test using RigiScan Plus in the evaluation of erectile dysfunction. Urol Int. 2004;72:221-224.
51. Montorsi F, Aversa A, Moncada I, Perimenis P, PorstH, Barker C, Shane MA, Sorsaburu S. A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are nai{dotless}̈ve to PDE5 inhibitors. J Sex Med. 2011;8:2617-2624.
52. Montorsi F, Briganti A, Salonia A, Rigatti P, Burnett AL. Current and future strategies for preventing and managing erectile dysfunction following radical prostatectomy. Eur Urol. 2004;45:123-133.
53. Montorsi F, Briganti A, Salonia A, Rigatti P, Margonato A, Macchi A, Galli S, Ravagnani PM, Montorsi P. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol. 2003;44:360-364.
54. Montorsi F, Guazzoni G, Strambi LF, Da Pozzo LF, Nava L, Barbieri L, Rigatti P, Pizzini G, Miani A. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol. 1997;158:1408-1410.
55. Mulhall J, Land S, Parker M, Waters WB, Flanigan RC. The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J Sex Med. 2005;2:532-540.
56. Nawawi H, Osman NS, Annuar R, Khalid BA, Yusoff K. Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin. Atherosclerosis. 2003;169:283-291.
57. Naya M, Tsukamoto T, InubushiM, Morita K, Katoh C, Furumoto T, Fujii S, TsutsuiH, Tamaki N. Elevated plasma plasminogen activator inhibitor type-1 is an independent predictor of coronary microvascular dysfunction in hypertension. Circulation J. 2007a;71:348-353.
58. Naya M, Tsukamoto T, Morita K, Katoh C, Furumoto T, Fujii S, Tamaki N, Tsutsui H. Plasma interleukin-6 and tumor necrosis factor-alpha can predict coronary endothelial dysfunction in hypertensive patients. Hypertens Res. 2007b;30:541-548.
59. Ohno Y, Hashiguchi T, Maenosono R, Yamashita H, Taira Y, Minowa K, Yamashita Y, Kato Y, Kawahara KI, Maruyama I. The diagnostic value of endothelial function as a potential sensor of fatigue in health. Vasc Health Risk Manag. 2010;6:135-144.
60. O'Leary MP, Althof SE, Cappelleri JC, Crowley A, Sherman N, Duttagupta S United States Self-Esteem and Relationship Questionnaire Study Group. Self-esteem, confidence and relationship satisfaction of men with erectile dysfunction treated with sildenafil citrate: a multicenter, randomized, parallel group, double-blind, placebo controlled study in the United States. J Urol. 2006;175:1058-1062.
61. Porst H, Giuliano F, Glina S, Ralph D, Casabé AR, Elion-Mboussa A, Shen W, Whitaker JS. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, doubleblind, placebo-controlled trial. Eur Urol. 2006;50:351-359.
62. Porst H, Glina S, Ralph D, Zeigler H, Wong DG, Woodward B. Durability of response following cessation of tadalafil taken once daily as treatment for erectile dysfunction. J Sex Med. 2010; 7:3487-3494.
63. Rajfer J, Aliotta PJ, Steidle CP, Fitch WP III, Zhao Y, Yu A. Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. Int J Impot Res. 2007;19:95-103.
64. Ralph D, Eardley I, Kell P, Dean J, Hackett G, Collins O, Edwards D. Improvement in erectile function on vardenafil treatment correlates with treatment satisfaction in both patients and their partners. Br J Urol Int. 2007;100:130-136.
65. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, Wang T, Gregg D, Ramaswami P, Pippen AM, Annex BH, Dong C, Taylor DA. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation. 2003;108:457-463.
66. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007;49:2129-2138.
67. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359:2195-2207.
68. Rosano GM, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol. 2005;47:214-220.
69. Rosen RC, Allen KR, Ni X, Araujo AB. Minimum clinically important differences in the erectile function domain of the International Index of Erectile Function Scale. Eur Urol. 2011;60:1010-1016.
70. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997; 49:822-830.
71. Rubinshtein R, Kuvin JT, Soffler M, Lennon RJ, Lavi S, Nelson RE, Pumper GM, Lerman LO, Lerman A. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J. 2010;31:1142-1148.
72. Rubio-Aurioles E, Kim ED, Rosen RC, Porst H, Burns P, Zeigler H, Wong DG. Impact on erectile function and sexual quality of life of couples: a double-blind, randomized, placebo-controlled trial of tadalafil taken once daily. J Sex Med. 2009;6:1314-1323.
73. Salama N. Nocturnal electrobioimpedance volumetric assessment in diabetic men with erectile dysfunction before and after tadalafil intake. Int J Impot Res. 2004;16:441-447.
74. Seftel A, Goldfischer E, Kim ED, Dula E, Zeigler H, Burns P. Onset of efficacy of tadalafil once daily in men with erectile dysfunction: a randomized, double-blind, placebo controlled trial. J Urol. 2011;185:243-248.
75. Seftel AD, Buvat J, Althof SE, McMurray JG, Zeigler HL, Burns PR, Wong DG. Improvements in confidence, sexual relationship and satisfaction measures: results of a randomized trial of tadalafil 5mg taken once daily. Int J Impot Res. 2009;21:240-248.
76. Shimizu M, Kario K. Role of the augmentation index in hypertension. Ther Adv Cardiovasc Dis. 2008;2:25-35.
77. Skoumal R, Chen J, Kula K, Breza J, Calomfirescu N, Basson BR, Kopernicky V. Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction. Eur Urol. 2004;46:362-369.
78. Steidle CP, Stecher VJ, Pace C, Tseng LJ. Correlation of improved erectile function and rate of successful intercourse with improved emotional well-being assessed with the Self-EsteemAnd Relationship questionnaire in men treated with sildenafil for erectile dysfunction and stratified by age. Curr Med Res Opin. 2006;22:939-948.
79. Suzuki K, Sato Y, Horita H, Adachi H, Kato R, Hisasue S, Itoh N, Tsukamoto T. The correlation between penile tumescence measured by the erectometer and penile rigidity by the RigiScan. Int J Urol. 2001;8:594-598.
80. Tamler R, Bar-Chama N. Assessment of endothelial function in the patient with erectile dysfunction: an opportunity for the urologist. Int J Impot Res. 2008;20:370-377.
81. Udelson D, Park K, Sadeghi-Nejad H, Salimpour P, Krane RJ, Goldstein I. Axial penile buckling forces vs. Rigiscan radial rigidity as a function of intracavernosal pressure: why Rigiscan does not predict functional erections in individual patients. Int J Impot Res. 1999;11:327-337.
82. Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher AM, Dimmeler S. Increase in circulating progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation. 2001;103:2885-2890.
83. Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol. 2003;189:98-101.
84. Yinon D, Lowenstein L, Suraya S, Beloosesky R, Zmora O, Malhotra A, Pillar G. Pre-eclampsia is associated with sleep-disordered breathing and endothelial dysfunction. Eur Respir J. 2006;27: 328-333.